Lakefront Biotherapeutics (LKFT) Share-based Compensation (2016 - 2020)

Lakefront Biotherapeutics (LKFT) has 5 years of Share-based Compensation data on file, last reported at $10.2 million in Q1 2020.

• Share-based Compensation for Q1 2020 came in at $10.2 million, up 49.36% year-over-year; the trailing twelve-month figure through Mar 2020 was $38.3 million (up 14.66% YoY), and the FY2023 annual result was $61.0 million, down 32.42% from the prior year.
• Share-based Compensation declined to $10.2 million in Q1 2020 per LKFT's latest filing, from $11.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $11.3 million in Q4 2019 and troughed at $2.1 million in Q1 2016.
• A 5-year average of $6.2 million and a median of $5.6 million in 2017 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2018 and 2019: Share-based Compensation jumped 180.78% in 2018, then climbed 12.63% in 2019.
• A 5-year view of Share-based Compensation shows it stood at $2.6 million in 2016, then soared by 34.63% to $3.6 million in 2017, then jumped by 180.78% to $10.0 million in 2018, then increased by 12.63% to $11.3 million in 2019, then declined by 9.51% to $10.2 million in 2020.
• Business Quant data shows LKFT's Share-based Compensation at $10.2 million in Q1 2020, $11.3 million in Q4 2019, and $6.8 million in Q1 2019.